Articles > Lymphoma

  1. Finding New Approaches to Immunotherapy

    Helen Heslop, M.D., leads a team of scientists being funded through LLS’s Specialized Center of Research Program (SCOR). The project brings together researchers from different institutions to test a half dozen novel approaches to cancer immunotherapy – all of which harness the patient's own immune system to fight the cancer. Heslop, a professor in the Department of Medicine and Pediatrics at Baylor College of Medicine and the director of the Center for Cell and Gene Therapy, pioneered...

    Read More
  2. Significant Advance for Hodgkin Lymphoma Patients

    The Food & Drug Administration’s accelerated approval of an immunotherapy for patients with Hodgkin lymphoma who have failed other treatments is a positive development for patients who face a very poor prognosis. While Hodgkin lymphoma is now considered one of the most curable forms of cancer – with a more than 86 percent five-year-survival rate overall – those patients who relapse after treatment have a much reduced chance of survival. FDA’s approval of nivolumab (Opdivo®)...

    Read More
  3. #ASH15 Day 4: Breakthrough Therapy Designation for Novel Immunotherapy

    Yesterday we learned the exciting news that the FDA has granted Breakthrough Therapy designation for an investigational immunotherapy LLS is supporting through our Therapy Acceleration Program (TAP). The therapy, KTE-C19, being developed by Kite Pharma, is another example of a chimeric antigen receptor (CAR), an approach that genetically engineers patients’ immune T cells and reintroduces them into the body to kill cancer cells. KTE-C19 is crafted by removing patients' T cells and geneti...

    Read More
  4. The First Official Day of #ASH15

    Beat AML is a collaboration launched nearly three years ago by LLS and the Knight Cancer Institute at Oregon Health & Science University (OHSU), to go on the offenensive against acute myeloid leukemia (AML), a blood cancer with a poor prognosis and little change in the standard of care in 40 years. More than a dozen abstracts from the first phase of the initiative will be featured throughout the American Society of Hematology (#ASH15) Annual Meeting in Orlando over the next few days. #...

    Read More
  5. Balancing Expenses of Cancer Care: Turning Monetary Woes into Financial Feats

    I would never have imagined that at the age of 29, I would be lying in intensive care fighting for my life with stage IV anaplastic large cell lymphoma (ALCL). What a wake-up call, literally! Nicknamed “Sleeping Beauty,” I woke up after three weeks to learn my true diagnosis following months of illness. By the time I opened my eyes, I had already undergone my first five-day round of chemotherapy…with five more sessions to go. It was going to be a long summer. But as it turns out, ...

    Read More